Ironwood Pharmaceuticals Inc
apraglutide
short bowel syndrome (SBS) with intestinal failure (SBS-IF)
Date
TBD
Advisory committee · Date TBD estimated
What's at stake
An FDA advisory committee reviews apraglutide for short bowel syndrome (SBS) with intestinal failure (SBS-IF) around Date TBD. The panel's public vote often front-runs the agency's final verdict — and the share price.
Primary source
· SEC 8-K
verified 15h ago
“On track to begin site initiations for Phase 3 confirmatory trial of apraglutide in short bowel syndrome with intestinal failure (SBS-IF) in the second quarter of 2026”